Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions

Abstract

Type 2 diabetes mellitus (T2D) is a pervasive metabolic disorder driven by insulin resistance and progressive pancreatic β-cell failure, with a rapidly growing global prevalence. Its pathogenesis now extends beyond hyperglycemia to encompass intricate immunometabolic dysregulation, mitochondrial dysfunction, and organelle stress. However, a cohesive synthesis that integrates these disparate molecular mechanisms with contemporary therapeutic advancements remains missing. This review systematically investigates the immunometabolic axis, highlighting macrophage polarization and exosomes, as well as nanotube-mediated crosstalk with β-cells, and describes how mitochondrial dynamics disorder and impaired mitophagy become the core driving factors for β-cell failure. Lipotoxicity mediated by ceramides, diacylglycerols, and cholesterol imbalance is critically analyzed alongside proteotoxicity from islet amyloid polypeptide aggregation. We then chart the therapeutic evolution from glucocentric strategies to modern complication-centric paradigms, emphasizing SGLT2 inhibitors and GLP-1 receptor agonists that confer proven cardio-renal protection. Personalized treatment, multiomics integration, next-generation precision therapies, and holistic art-based interventions that promote sustainable lifestyle changes are further discussed. By connecting molecular insights to clinical application, this review provides a comprehensive resource for researchers and clinicians, aiming to advance T2D management and improve global patient outcomes.

Keywords

β-cell dysfunction / mitochondrial dynamics / molecular pathogenesis / therapeutic interventions / Type 2 diabetes

References

[1] Global, Regional, and National Burden of Diabetes From 1990 to 2021, With Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021, Lancet 2023. 402(10397): 203–234.

[2] R. Taylor, “Understanding the Cause of Type 2 Diabetes,” The Lancet Diabetes & Endocrinology 12, no. 9 (2024): 664–673.

[3] M. Orabi, M. S. Yeganeh, T. Chun, and J. F. Lo, “Modeling Adipokine and Insulin-Mediated Crosstalk between Adipocytes and Beta Cells Using Flow-Enabled Microfluidics,” Small 21, no. 35 (2025): e2504686.

[4] M. Cutolo, S. Soldano, V. Smith, E. Gotelli, and E. Hysa, “Dynamic Macrophage Phenotypes in Autoimmune and Inflammatory Rheumatic Diseases,” Nat Rev Rheumatol 21, no. 9 (2025): 546–565.

[5] P. N. Zakharov, C. S. Chowdhury, O. J. Peterson, et al., “Efferocytic Remodelling of Pancreatic Islet Macrophages by Limited Beta-cell Death,” Nature 647, no. 8091 (2025): 1014–1024.

[6] S. Hakim, A. Jain, S. S. Adamson, et al., “Macrophages Protect Against Sensory Axon Loss in Peripheral Neuropathy,” Nature 640, no. 8057 (2025): 212–220.

[7] R. Jacks and C. Lumeng, “Macrophage and T Cell Networks in Adipose Tissue,” Nature Reviews Endocrinology 20, no. 1 (2024): 50–61.

[8] G. Basile, A. Vetere, J. Hu, et al., “Excess Pancreatic Elastase Alters Acinar-beta Cell Communication by Impairing the Mechano-signaling and the PAR2 Pathways,” Cell Metabolism 35, no. 7 (2023): 1242–1260.e9.

[9] Z. Gan, M. Zhao, Y. Xia, Y. Yan, and W. Ren, “Carbon Metabolism in the Regulation of Macrophage Functions,” Trends in Endocrinology and Metabolism 35, no. 1 (2024): 62–73.

[10] J. Yang, N. Singh, C. Xu, et al., “STK11 coordinates IL-4 Signaling With Metabolic Reprogramming to Control M2 Macrophage Polarization and Antitumor Immunity,” Science Advances 11, no. 39 (2025): eadx5495.

[11] C. Xu, W. Li, J. Mao, et al., “Using Chondroitin Sulfate Lithium Hydrogel for Diabetic Bone Regeneration via Regulation of Macrophage Polarization,” Carbohydrate Polymers 347 (2025): 122787.

[12] L. Wang, Z. Wu, X. Chen, et al., “A Multifunctional Self-assembled Hydrogel With Bactericidal Activity and Macrophage Metabolic Reprogramming for Diabetic Bone Defect Repair,” Mater Today Bio 34 (2025): 102162.

[13] K. Singh, A. K. Koroma, R. K. Pandey, et al., “Restoring Histone Acetylation Accelerates Diabetic Wound Repair by Improving the Spatiotemporal Dynamics of Macrophages,” Adv Sci (Weinh) 1246 (2025): e04920.

[14] R. Lin, Y. Zhu, Y. Liu, et al., “Sirtuins Regulate Macrophage Polarization in Heart Failure: Metabolic Reprogramming, Epigenetic Regulation, and Immune Cell Interactions,” Pharmacological Research 220 (2025): 107936.

[15] G. Xiang, K. Liu, T. Wang, et al., “Situ Regulation of Macrophage Polarization to Enhance Osseointegration under Diabetic Conditions Using Injectable Silk/Sitagliptin Gel Scaffolds,” Adv Sci (Weinh) 8, no. 3 (2021): 2002328.

[16] G. Yang, H. Kang, Y. Zhu, et al., “Bacteria Microenvironment-responsive Missile Microneedles Modulate Immunity and Penetrate Biofilm for Diabetic Wound Therapy,” Bioact Mater 55 (2026): 426–445.

[17] X. Jiang, J. Ma, K. Xue, et al., “Highly Bioactive MXene-M2-Exosome Nanocomposites Promote Angiogenic Diabetic Wound Repair Through Reconstructing High Glucose-Derived Immune Inhibition,” ACS Nano 18, no. 5 (2024): 4269–4286.

[18] R. Zhang, A. Li, X. Zhao, et al., “Identification of SEC16B as a Novel Regulator of Glucose Homeostasis,” Diabetologia 68, no. 10 (2025): 2247–2262.

[19] V. Sidarala, J. Zhu, E. Levi-D'Ancona, et al., “Mitofusin 1 and 2 Regulation of Mitochondrial DNA Content Is a Critical Determinant of Glucose Homeostasis,” Nature Communications 13, no. 1 (2022): 2340.

[20] E. M. Walker, G. L. Pearson, N. Lawlor, et al., “Retrograde Mitochondrial Signaling Governs the Identity and Maturity of Metabolic Tissues,” Science 388, no. 6743 (2025): eadf2034.

[21] W. Tseng, C. Chu, Y. Lee, et al., “Metabolic Regulation of Mitochondrial Morphologies in Pancreatic Beta Cells: Coupling of Bioenergetics and Mitochondrial Dynamics,” Communications Biology 7, no. 1 (2024): 1267.

[22] J. Wang, Z. Qi, Y. Wu, et al., “Discovery of IHMT-MST1-39 as a Novel MST1 Kinase Inhibitor and AMPK Activator for the Treatment of Diabetes Mellitus,” Signal Transduct Target Ther 8, no. 1 (2023): 143.

[23] K. Park and M. Lee, “Essential Role of Lysosomal Ca2+-mediated TFEB Activation in Mitophagy and Functional Adaptation of Pancreatic Beta-cells to Metabolic Stress,” Autophagy 18, no. 12 (2022): 3043–3045.

[24] H. Xian and Y. Liou, “Functions of Outer Mitochondrial Membrane Proteins: Mediating the Crosstalk Between Mitochondrial Dynamics and Mitophagy,” Cell Death and Differentiation 28, no. 3 (2021): 827–842.

[25] B. Liu, D. Hua, L. Shen, et al., “NPC1 is Required for Postnatal Islet Beta Cell Differentiation by Maintaining Mitochondria Turnover,” Theranostics 14, no. 5 (2024): 2058–2074.

[26] J. Ge, S. L. Shelby, Y. Wang, et al., “Cardioprotective Properties of Quercetin in Fescue Toxicosis-induced Cardiotoxicity via Heart-gut Axis in Lambs (Ovis Aries),” Journal of Hazardous Materials 458 (2023): 131843.

[27] J. Nah, A. Shirakabe, R. Mukai, et al., “Ulk1-dependent Alternative Mitophagy Plays a Protective Role During Pressure Overload in the Heart,” Cardiovascular Research 118, no. 12 (2022): 2638–2651.

[28] K. Park, H. Lim, J. Kim, et al., “Lysosomal Ca(2+)-mediated TFEB Activation Modulates Mitophagy and Functional Adaptation of Pancreatic Beta-cells to Metabolic Stress,” Nature Communications 13, no. 1 (2022): 1300.

[29] C. Zhang, X. Gao, M. Li, et al., “The Role of Mitochondrial Quality Surveillance in Skin Aging: Focus on Mitochondrial Dynamics, Biogenesis and Mitophagy,” Ageing Research Reviews 87 (2023): 101917.

[30] L. Chen, Y. Lin, X. Zhu, et al., “MCT1-mediated Lactate Shuttle to Mitochondria Governs Macrophage Polarization and Modulates Glucose Homeostasis by Affecting Beta Cells,” Adv Sci (Weinh) 12, no. 38 (2025): e14760.

[31] X. Chen, J. Shao, I. Brandenburger, et al., “FFAR4-mediated IL-6 Release From Islet Macrophages Promotes Insulin Secretion and Is Compromised in Type-2 Diabetes,” Nature Communications 16, no. 1 (2025): 3422.

[32] J. Zuo, Q. Guo, Y. Fan, et al., “Self-powered Intracellular Nanogenerator Attenuates Inflammatory Osteolysis Through Mitochondrial MRS2/Mg(2+)-mediated Macrophage Repolarization and Osteoclastogenesis Inhibition,” Mater Today Bio 33 (2025): 102050.

[33] J. Li, X. Li, L. W. C. Chan, et al., “Lipotoxicity-polarised Macrophage-derived Exosomes Regulate Mitochondrial Fitness Through Miro1-mediated Mitophagy Inhibition and Contribute to Type 2 Diabetes Development in Mice,” Diabetologia 66, no. 12 (2023): 2368–2386.

[34] L. Chen, P. Hu, X. Hong, et al., “Dimethyl Fumarate Modulates M1/M2 Macrophage Polarization to Ameliorate Periodontal Destruction by Increasing TUFM-mediated Mitophagy,” Int J Oral Sci 17, no. 1 (2025): 32.

[35] Y. Wang, Z. Wang, W. Diao, et al., “Islet Tissue Macrophages in Immunity Homeostasis and Type 1 Diabetes,” Clinical Reviews in Allergy & Immunology 68, no. 1 (2025): 82.

[36] D. J. Fazakerley, J. van Gerwen, K. C. Cooke, et al., “Phosphoproteomics Reveals Rewiring of the Insulin Signaling Network and Multi-nodal Defects in Insulin Resistance,” Nature Communications 14, no. 1 (2023): 923.

[37] H. Xiao, X. Sun, Z. Lin, et al., “Gentiopicroside Targets PAQR3 to Activate the PI3K/AKT Signaling Pathway and Ameliorate Disordered Glucose and Lipid Metabolism,” Acta Pharm Sin B 12, no. 6 (2022): 2887–2904.

[38] A. Kumar, K. Sundaram, J. Mu, et al., “High-fat Diet-induced Upregulation of Exosomal Phosphatidylcholine Contributes to Insulin Resistance,” Nature Communications 12, no. 1 (2021): 213.

[39] B. Zhang, L. Yu, R. Zhu, et al., “Malting Barley Carbon Dots-mediated Oxidative Stress Promotes Insulin Resistance in Mice via NF-kappaB Pathway and MAPK Cascade,” J Nanobiotechnology 20, no. 1 (2022): 331.

[40] E. J. Needham, J. R. Hingst, J. D. Onslev, et al., “Personalized Phosphoproteomics of Skeletal Muscle Insulin Resistance and Exercise Links MINDY1 to Insulin Action,” Cell Metabolism 36, no. 12 (2024): 2542–2559.e6.

[41] Y. Wang, M. Li, L. Chen, et al., “Natural Killer Cell-derived Exosomal miR-1249-3p Attenuates Insulin Resistance and Inflammation in Mouse Models of Type 2 Diabetes,” Signal Transduct Target Ther 6, no. 1 (2021): 409.

[42] P. Li, K. Li, W. Yuan, et al., “1alpha,25(OH)(2)D(3) Ameliorates Insulin Resistance by Alleviating Gammadelta T Cell Inflammation via Enhancing Fructose-1,6-bisphosphatase 1 Expression,” Theranostics 13, no. 15 (2023): 5290–5304.

[43] J. Kjærgaard, B. Stocks, J. Henderson, et al., “Personalized Molecular Signatures of Insulin Resistance and Type 2 Diabetes,” Cell 188, no. 15 (2025): 4106–4122.e16.

[44] K. Sarkar, S. Bank, A. Chatterjee, et al., “Hyaluronic Acid-graphene Oxide Quantum Dots Nanoconjugate as Dual Purpose Drug Delivery and Therapeutic Agent in Meta-inflammation,” J Nanobiotechnology 21, no. 1 (2023): 246.

[45] Y. Li, S. Gao, S. Shi, et al., “Tetrahedral Framework Nucleic Acid-Based Delivery of Resveratrol Alleviates Insulin Resistance: From Innate to Adaptive Immunity,” Nanomicro Lett 13, no. 1 (2021): 86.

[46] H. Cho, C. Lai, R. Bonnavion, et al., “Endothelial Insulin Resistance Induced by Adrenomedullin Mediates Obesity-associated Diabetes,” Science 387, no. 6734 (2025): 674–682.

[47] L. Mastrototaro and M. Roden, “Insulin Resistance and Insulin Sensitizing Agents,” Metabolism 125 (2021): 154892.

[48] N. J. Pillon, R. J. Loos, S. M. Marshall, and J. R. Zierath, “Metabolic Consequences of Obesity and Type 2 Diabetes: Balancing Genes and Environment for Personalized Care,” Cell 184, no. 6 (2021): 1530–1544.

[49] J. Yong, V. S. Parekh, S. M. Reilly, et al., “Chop/Ddit3 Depletion in Beta Cells Alleviates ER Stress and Corrects Hepatic Steatosis in Mice,” Science Translational Medicine 13, no. 604 (2021): eaba9796.

[50] G. Xourafa, M. Korbmacher, and M. Roden, “Inter-organ Crosstalk During Development and Progression of Type 2 Diabetes Mellitus,” Nature Reviews Endocrinology 20, no. 1 (2024): 27–49.

[51] Y. Yang and E. Seki, “Global Spread of a Local Fire: Transmission of Endoplasmic Reticulum Stress via Connexin 43,” Cell Metabolism 33, no. 2 (2021): 229–230.

[52] E. K. Sokolowski, R. Kursawe, V. Selvam, et al., “Multi-omic human Pancreatic Islet Endoplasmic Reticulum and Cytokine Stress Response Mapping Provides Type 2 Diabetes Genetic Insights,” Cell Metabolism 36, no. 11 (2024): 2468–2488.e7.

[53] A. Beaulant, M. Dia, B. Pillot, et al., “Endoplasmic Reticulum-mitochondria Miscommunication Is an Early and Causal Trigger of Hepatic Insulin Resistance and Steatosis,” Journal of Hepatology 77, no. 3 (2022): 710–722.

[54] T. Dos Reis Araujo, J. A. da Silva Junior, B. L. Alves, et al., “Disruption of Mitochondria-associated Membranes Contributes to the Dysregulation of Insulin Secretion in Undernutrition, Obesity, and Double Burden of Malnutrition,” Metabolism 173 (2025): 156393.

[55] C. Chen, B. Guan, M. R. Alzahrani, et al., “Adaptation to Chronic ER Stress Enforces Pancreatic Beta-cell Plasticity,” Nature Communications 13, no. 1 (2022): 4621.

[56] K. Amo-Shiinoki, K. Tanabe, W. Nishimura, et al., “beta Cell Dedifferentiation, the Underlying Mechanism of Diabetes in Wolfram Syndrome,” Science Translational Medicine 17, no. 786 (2025): eadp2332.

[57] J. Yue, X. Sun, X. Duan, et al., “Triphenyl Phosphate Proved More Potent Than Its Metabolite Diphenyl Phosphate in Inducing Hepatic Insulin Resistance Through Endoplasmic Reticulum Stress,” Environment International 172 (2023): 107749.

[58] S. Bilekova, S. Sachs, and H. Lickert, “Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells,” Trends in Pharmacological Sciences 42, no. 2 (2021): 85–95.

[59] M. Lytrivi, Y. Tong, E. Virgilio, X. Yi, and M. Cnop, “Diabetes Mellitus and the Key Role of Endoplasmic Reticulum Stress in Pancreatic Beta Cells,” Nature Reviews Endocrinology 21, no. 9 (2025): 546–563.

[60] M. Fiorenza, J. Onslev, C. Henríquez-Olguín, et al., “Reducing the Mitochondrial Oxidative Burden Alleviates Lipid-induced Muscle Insulin Resistance in Humans,” Science Advances 10, no. 44 (2024): eadq4461.

[61] J. Sastre, S. Pérez, L. Sabater, and S. Rius-Pérez, “Redox Signaling in the Pancreas in Health and Disease,” Physiological Reviews 105, no. 2 (2025): 593–650.

[62] S. Baumel-Alterzon, L. S. Katz, G. Brill, A. Garcia-Ocaña, and D. K. Scott, “Nrf2: The Master and Captain of Beta Cell Fate,” Trends in Endocrinology and Metabolism 32, no. 1 (2021): 7–19.

[63] Q. Huang, Z. Liu, Y. Yang, et al., “Selenium Nanodots (SENDs) as Antioxidants and Antioxidant-Prodrugs to Rescue Islet Beta Cells in Type 2 Diabetes Mellitus by Restoring Mitophagy and Alleviating Endoplasmic Reticulum Stress,” Adv Sci (Weinh) 10, no. 19 (2023): e2300880.

[64] P. Carapeto, K. Iwasaki, F. Hela, et al., “Exercise Activates AMPK in Mouse and human Pancreatic Islets to Decrease Senescence,” Nat Metab 6, no. 10 (2024): 1976–1990.

[65] U. Karunakaran, S. Elumalai, S. M. Chung, K. Maedler, K. C. Won, and J. S. Moon, “Mitochondrial Aldehyde Dehydrogenase-2 Coordinates the Hydrogen Sulfide—AMPK Axis to Attenuate High Glucose-induced Pancreatic Beta-cell Dysfunction by Glutathione Antioxidant System,” Redox Biology 69 (2024): 102994.

[66] Y. Sung, Y. Yu, and J. Han, “Nutrient Sensors and Their Crosstalk,” Experimental & Molecular Medicine 55, no. 6 (2023): 1076–1089.

[67] U. M. Parmar, M. P. Jalgaonkar, Y. A. Kulkarni, and M. J. Oza, “Autophagy-nutrient Sensing Pathways in Diabetic Complications,” Pharmacological Research 184 (2022): 106408.

[68] X. Hu and F. Guo, “Amino Acid Sensing in Metabolic Homeostasis and Health,” Endocrine Reviews 42, no. 1 (2021): 56–76.

[69] F. A. Duca, T. M. Z. Waise, W. T. Peppler, and T. K. T. Lam, “The Metabolic Impact of Small Intestinal Nutrient Sensing,” Nature Communications 12, no. 1 (2021): 903.

[70] M. A. Hill, Y. Yang, L. Zhang, et al., “Insulin Resistance, Cardiovascular Stiffening and Cardiovascular Disease,” Metabolism 119 (2021): 154766.

[71] C. Andriessen, C. E. Fealy, A. Veelen, et al., “Three Weeks of Time-restricted Eating Improves Glucose Homeostasis in Adults With Type 2 Diabetes but Does Not Improve Insulin Sensitivity: A Randomised Crossover Trial,” Diabetologia 65, no. 10 (2022): 1710–1720.

[72] R. Wang, S. Gu, Y. H. Kim, A. Lee, H. Lin, and D. Jiang, “Diabetic Wound Repair: From Mechanism to Therapeutic Opportunities,” MedComm 6, no. 10 (2025): e70406 (2020).

[73] L. L. V. Møller, M. S. Ali, J. Davey, et al., “The Rho Guanine Dissociation Inhibitor Alpha Inhibits Skeletal Muscle Rac1 Activity and Insulin Action,” PNAS 120, no. 27 (2023): e2211041120.

[74] W. Ying, H. Gao, F. C. G. Dos Reis, et al., “MiR-690, an Exosomal-derived miRNA From M2-polarized Macrophages, Improves Insulin Sensitivity in Obese Mice,” Cell metabolism 33, no. 4 (2021): 781–790.e5.

[75] S. Silvano, T. Napolitano, M. Plaisant, et al., “RSPO1, a Potent Inducer of Pancreatic Beta Cell Neogenesis,” Cell Rep Med 6, no. 5 (2025): 102126.

[76] K. Katsumoto, S. Yennek, C. Chen, et al., “Wnt4 is Heterogeneously Activated in Maturing Beta-cells to Control Calcium Signaling, Metabolism and Function,” Nature Communications 13, no. 1 (2022): 6255.

[77] X. Chen, H. Tan, J. Xu, et al., “Klotho-derived Peptide 6 Ameliorates Diabetic Kidney Disease by Targeting Wnt/Beta-catenin Signaling,” Kidney International 102, no. 3 (2022): 506–520.

[78] E. Ilegems, G. Bryzgalova, J. Correia, et al., “HIF-1alpha Inhibitor PX-478 Preserves Pancreatic Beta Cell Function in Diabetes,” Science Translational Medicine 14, no. 638 (2022): eaba9112.

[79] B. Zhu, Y. Wu, S. Huang, et al., “Uncoupling of Macrophage Inflammation From Self-renewal Modulates Host Recovery From respiratory Viral Infection,” Immunity 54, no. 6 (2021): 1200–1218.e9.

[80] Y. Lei, Q. Liu, B. Chen, et al., “Protein O-GlcNAcylation Coupled to Hippo Signaling Drives Vascular Dysfunction in Diabetic Retinopathy,” Nature Communications 15, no. 1 (2024): 9334.

[81] A. Ardestani and K. Maedler, “Deathly Triangle for Pancreatic Beta-cells: Hippo Pathway-MTORC1-autophagy,” Autophagy 12 (2021): 4494–4496.

[82] T. Yuan, K. Annamalai, S. Naik, et al., “The Hippo Kinase LATS2 Impairs Pancreatic Beta-cell Survival in Diabetes Through the mTORC1-autophagy Axis,” Nature Communications 12, no. 1 (2021): 4928.

[83] J. Chen, X. Wang, Q. He, H. Yang, A. B. Fogo, and R. C. Harris, “Inhibition of Transcriptional Coactivator YAP Impairs the Expression and Function of Transcription Factor WT1 in Diabetic Podocyte Injury,” Kidney International 105, no. 6 (2024): 1200–1211.

[84] S. Choi, S. P. Hong, J. H. Bae, et al., “Hyperactivation of YAP/TAZ Drives Alterations in Mesangial Cells Through Stabilization of N-Myc in Diabetic Nephropathy,” Journal of the American Society of Nephrology 34, no. 5 (2023): 809–828.

[85] B. Zhong, J. Liu, H. H. Ong, et al., “Hypoxia-reduced YAP Phosphorylation Enhances Expression of Mucin5AC in Nasal Epithelial Cells of Chronic Rhinosinusitis With Nasal Polyps,” Allergy 80, no. 5 (2025): 1271–1285.

[86] C. Castillo, M. Grieco, S. D'Amone, M. G. Lolli, O. Ursini, and B. Cortese, “Hypoxia Effects on Glioblastoma Progression Through YAP/TAZ Pathway Regulation,” Cancer Letters 588 (2024): 216792.

[87] J. Guo, M. Wang, S. Yuan, et al., “Photo-controlled co-delivery of Verteporfin and Acriflavine via Platelets Achieves Potentiated Glioblastoma-targeted Photodynamic Therapy,” J Nanobiotechnology 23, no. 1 (2025): 371.

[88] T. Scherer, K. Sakamoto, and C. Buettner, “Brain Insulin Signalling in Metabolic Homeostasis and Disease,” Nature reviews Endocrinology 17, no. 8 (2021): 468–483.

[89] D. E. James, J. Stöckli, and M. J. Birnbaum, “The Aetiology and Molecular Landscape of Insulin Resistance,” Nature Reviews Molecular Cell Biology 22, no. 11 (2021): 751–771.

[90] B. He, K. D. Copps, O. Stöhr, et al., “Spatial Regulation of Glucose and Lipid Metabolism by Hepatic Insulin Signaling,” Cell metabolism 37, no. 7 (2025): 1568–1583.e7.

[91] D. Ferguson and B. Finck, “Emerging Therapeutic Approaches for the Treatment of NAFLD and Type 2 Diabetes Mellitus,” Nature reviews Endocrinology 17, no. 8 (2021): 484–495.

[92] S. Demir, P. P. Nawroth, S. Herzig, and B. Ekim Üstünel, “Emerging Targets in Type 2 Diabetes and Diabetic Complications,” Adv Sci (Weinh) 8, no. 18 (2021): e2100275.

[93] P. N. Zakharov, C. S. Chowdhury, O. J. Peterson, et al., “Efferocytic Remodelling of Pancreatic Islet Macrophages by Limited Beta-cell Death,” Nature 647, no. 8091 (2025): 1014–1024.

[94] L. Wigger, M. Barovic, A. Brunner, et al., “Multi-omics Profiling of Living human Pancreatic Islet Donors Reveals Heterogeneous Beta Cell Trajectories towards Type 2 Diabetes,” Nat Metab 3, no. 7 (2021): 1017–1031.

[95] J. Son, W. Du, M. Esposito, et al., “Genetic and Pharmacologic Inhibition of ALDH1A3 as a Treatment of Beta-cell Failure,” Nature Communications 14, no. 1 (2023): 558.

[96] R. B. Kang, M. Varela, E. Oh, et al., “Human Pancreatic Alpha-cell Heterogeneity and Trajectory Inference Analyses Reveal SMOC1 as a Beta-cell Dedifferentiation Gene,” Nature Communications 16, no. 1 (2025): 8434.

[97] F. Liu, G. Liu, J. Song, et al., “BRD4 Signaling Maintains the Differentiated State of Beta Cells,” Adv Sci (Weinh) 12, no. 33 (2025): e05659.

[98] Y. Zhou, L. Hu, R. Zhuang, et al., “METRNL Represses Beta-to-alpha Cell Trans-differentiation to Maintain Beta Cell Function Under Diabetic Metabolic Stress in Mice,” Diabetologia 68, no. 8 (2025): 1769–1788.

[99] X. Tang, S. Uhl, T. Zhang, et al., “SARS-CoV-2 Infection Induces Beta Cell Transdifferentiation,” Cell metabolism 33, no. 8 (2021): 1577–1591.e7.

[100] M. Patra, A. Klochendler, R. Condiotti, et al., “Senescence of human Pancreatic Beta Cells Enhances Functional Maturation Through Chromatin Reorganization and Promotes Interferon Responsiveness,” Nucleic Acids Res 52, no. 11 (2024): 6298–6316.

[101] J. Li, X. Wang, Z. Yao, et al., “NLRP3-Dependent Crosstalk Between Pyroptotic Macrophage and Senescent Cell Orchestrates Trauma-Induced Heterotopic Ossification during Aberrant Wound Healing,” Adv Sci (Weinh) 10, no. 19 (2023): e2207383.

[102] L. Ma, Y. Han, Z. Chen, et al., “Transition of Cellular Senescence to Pyroptosis Mediates Recurrence of Small Cell Lung Cancer After Chemotherapy,” Science Advances 11, no. 28 (2025): eadw1553.

[103] B. Stockwell, J. P. Friedmann Angeli, H. Bayir, et al., “Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism,” Redox Biology, and Disease Cell 171, no. 2 (2017): 273–285.

[104] D. Zhong, Z. Wan, J. Cai, et al., “mPGES-2 Blockade Antagonizes Beta-cell Senescence to Ameliorate Diabetes by Acting on NR4A1,” Nat Metab 4, no. 2 (2022): 269–283.

[105] H. Fu, X. Zhou, D. Qin, et al., “Inhibition of Ferroptosis Delays Aging and Extends Healthspan across Multiple Species,” Adv Sci (Weinh) 12, no. 22 (2025): e2416559.

[106] P. Zhao, S. Yin, Y. Qiu, C. Sun, and H. Yu, “Ferroptosis and Pyroptosis Are Connected Through Autophagy: A New Perspective of Overcoming Drug Resistance,” Molecular cancer 24, no. 1 (2025): 23.

[107] H. Wang, L. Shu, C. Lv, et al., “BRCC36 Deubiquitinates HMGCR to Regulate the Interplay between Ferroptosis and Pyroptosis,” Adv Sci (Weinh) 11, no. 11 (2024): e2304263.

[108] H. Hua, Y. Wang, X. Wang, et al., “Remodeling Ceramide Homeostasis Promotes Functional Maturation of human Pluripotent Stem Cell-derived Beta Cells,” Cell Stem Cell 31, no. 6 (2024): 850–865.e10.

[109] S. Li, X. Dong, K. Gao, et al., “PP2A Promotes the Symmetric Division of MUC1-Dominant Cancer Stem-Like Cells in Small Cell Lung Cancer,” Adv Sci (Weinh) 12, no. 25 (2025): e2503545.

[110] S. Velagapudi, G. Karsai, M. Karsai, et al., “Inhibition of De Novo Ceramide Synthesis by Sirtuin-1 Improves Beta-cell Function and Glucose Metabolism in Type 2 Diabetes,” Cardiovascular Research 120, no. 11 (2024): 1265–1278.

[111] Y. Gao, N. Mi, W. Wu, et al., “Transfer of Inflammatory Mitochondria via Extracellular Vesicles From M1 Macrophages Induces Ferroptosis of Pancreatic Beta Cells in Acute Pancreatitis,” Journal of Extracellular Vesicles 13, no. 2 (2024): e12410.

[112] F. Huang, H. Wang, T. Yang, et al., “Ceramides Increase Mitochondrial Permeabilization to Trigger mtDNA-dependent Inflammation in Astrocytes During Brain Ischemia,” Metabolism 166 (2025): 156161.

[113] A. M. Poss, B. Krick, J. A. Maschek, et al., “Following Roux-en-Y Gastric Bypass Surgery, Serum Ceramides Demarcate Patients That Will Fail to Achieve Normoglycemia and Diabetes Remission,” Med 3, no. 7 (2022): 452–467.e4.

[114] S. S. Katti, I. V. Krieger, J. Ann, J. Lee, J. C. Sacchettini, and T. I. Igumenova, “Structural Anatomy of Protein Kinase C C1 Domain Interactions With Diacylglycerol and Other Agonists,” Nature Communications 13, no. 1 (2022): 2695.

[115] J. Zheng, R. C. Gaspar, I. Sakuma, et al., “Cideb Knockdown in Mice Increases Mitochondrial Fat Oxidation and Reverses Hepatic Steatosis and Insulin Resistance by the Plasma Membrane sn-1,2-DAGs-PKCepsilon-insulin Receptor Kinase(T1150) Pathway,” Diabetologia 68, no. 12 (2025): 2906–2920.

[116] Q. Su, J. Zhang, W. Lin, et al., “Sensitive Fluorescent Biosensor Reveals Differential Subcellular Regulation of PKC,” Nature Chemical Biology 21, no. 4 (2025): 501–511.

[117] J. Ding, A. T. Nguyen, K. Lohman, et al., “LXR Signaling Pathways Link Cholesterol Metabolism With Risk for Prediabetes and Diabetes,” Journal of Clinical Investigation 134, no. 10 (2024): e173278.

[118] A. Marku, L. Da Dalt, A. Galli, et al., “Pancreatic PCSK9 Controls the Organization of the Beta-cell Secretory Pathway via LDLR-cholesterol Axis,” Metabolism 136 (2022): 155291.

[119] M. Xu, S. Jiang, S. Tang, et al., “Nuclear SREBP2 Condensates Regulate the Transcriptional Activation of Lipogenic Genes and Cholesterol Homeostasis,” Nat Metab 7, no. 5 (2025): 1034–1051.

[120] X. Lu, Q. Xie, X. Pan, et al., “Type 2 Diabetes Mellitus in Adults: Pathogenesis, Prevention and Therapy,” Signal Transduct Target Ther 9, no. 1 (2024): 262.

[121] N. Stefan and K. Cusi, “A Global View of the Interplay Between Non-alcoholic Fatty Liver Disease and Diabetes,” The Lancet Diabetes & Endocrinology 10, no. 4 (2022): 284–296.

[122] T. Bo, L. Gao, Z. Yao, et al., “Hepatic Selective Insulin Resistance at the Intersection of Insulin Signaling and Metabolic Dysfunction-associated Steatotic Liver Disease,” Cell metabolism 36, no. 5 (2024): 947–968.

[123] A. K. Gattu, M. Tanzer, T. M. Yaron-Barir, et al., “Cell-intrinsic Insulin Signaling Defects in human iPS Cell-derived Hepatocytes in Type 2 Diabetes,” Journal of Clinical Investigation 135, no. 8 (2025): e183513.

[124] K. Ter Horst, D. F. Vatner, D. Zhang, et al., “Hepatic Insulin Resistance Is Not Pathway Selective in Humans with Nonalcoholic Fatty Liver Disease,” Diabetes Care 44, no. 2 (2021): 489–498.

[125] R. Vangoitsenhoven, R. L. Wilson, D. V. Cherla, et al., “Presence of Liver Steatosis Is Associated with Greater Diabetes Remission after Gastric Bypass Surgery,” Diabetes Care 44, no. 2 (2021): 321–325.

[126] R. Wagner, S. S. Eckstein, H. Yamazaki, et al., “Metabolic Implications of Pancreatic Fat Accumulation,” Nature reviews Endocrinology 18, no. 1 (2022): 43–54.

[127] N. J. Dyson, N. Kattner, Y. Al-Selwi, et al., “Quantitative Analysis of human Adult Pancreatic Histology Reveals Separate Fatty and Fibrotic Phenotypes in Type 2 Diabetes,” Diabetologia 68, no. 12 (2025): 2840–2853.

[128] S. Sharifi, T. Yamamoto, A. Zeug, M. Elsner, E. Avezov, and I. Mehmeti, “Non-esterified Fatty Acid Palmitate Facilitates Oxidative Endoplasmic Reticulum Stress and Apoptosis of Beta-cells by Upregulating ERO-1alpha Expression,” Redox Biology 73 (2024): 103170.

[129] Y. Yeh, C. Sona, X. Yan, et al., “Restoration of PITPNA in Type 2 Diabetic human Islets Reverses Pancreatic Beta-cell Dysfunction,” Nature Communications 14, no. 1 (2023): 4250.

[130] R. Alén, I. Garcia-Martinez, N. Cobo-Vuilleumier, et al., “Effect of Lipotoxic Hepatocyte-derived Extracellular Vesicles in Pancreas Inflammation: Essential Role of Macrophage TLR4 in Beta Cell Functionality,” Diabetologia 68, no. 8 (2025): 1801–1822.

[131] F. D'Addio, A. Maestroni, E. Assi, et al., “The IGFBP3/TMEM219 Pathway Regulates Beta Cell Homeostasis,” Nature Communications 13, no. 1 (2022): 684.

[132] C. L. Axelrod, C. E. Fealy, M. L. Erickson, et al., “Lipids Activate Skeletal Muscle Mitochondrial Fission and Quality Control Networks to Induce Insulin Resistance in Humans,” Metabolism 121 (2021): 154803.

[133] P. J. Ferrara, X. Rong, J. A. Maschek, et al., “Lysophospholipid Acylation Modulates Plasma Membrane Lipid Organization and Insulin Sensitivity in Skeletal Muscle,” Journal of Clinical Investigation 131, no. 8 (2021): e135963.

[134] L. Sylow, V. L. Tokarz, E. A. Richter, and A. Klip, “The Many Actions of Insulin in Skeletal Muscle, the Paramount Tissue Determining Glycemia,” Cell metabolism 33, no. 4 (2021): 758–780.

[135] M. Hendlinger, L. Mastrototaro, M. Exterkate, et al., “Exercise Training Increases Skeletal Muscle Sphingomyelinases and Affects Mitochondrial Quality Control in Men With Type 2 Diabetes,” Metabolism 172 (2025): 156361.

[136] K. E. Merz, J. Hwang, C. Zhou, et al., “Enrichment of the Exocytosis Protein STX4 in Skeletal Muscle Remediates Peripheral Insulin Resistance and Alters Mitochondrial Dynamics via Drp1,” Nature Communications 13, no. 1 (2022): 424.

[137] K. Whytock and B. Goodpaster, “Unraveling Skeletal Muscle Insulin Resistance: Molecular Mechanisms and the Restorative Role of Exercise,” Circulation Research 137, no. 2 (2025): 184–204.

[138] L. Fan, D. R. Sweet, D. A. Prosdocimo, et al., “Muscle Kruppel-Like Factor 15 Regulates Lipid Flux and Systemic Metabolic Homeostasis,” Journal of Clinical Investigation 131, no. 4 (2021): e139496.

[139] A. S. Bortoletto, W. V. Graham, G. Trout, et al., “Human Islet Amyloid Polypeptide (hIAPP) Protofibril-Specific Antibodies for Detection and Treatment of Type 2 Diabetes,” Adv Sci (Weinh) 9, no. 34 (2022): e2202342.

[140] F. Wirth, F. D. Heitz, C. Seeger, et al., “A human Antibody Against Pathologic IAPP Aggregates Protects Beta Cells in Type 2 Diabetes Models,” Nature Communications 14, no. 1 (2023): 6294.

[141] V. S. Mithu, K. Giller, E. Nimerovsky, et al., “The Structure of Human IAPP Fibrils Reflects Membrane and pH Conditions,” Journal of the American Chemical Society 147, no. 32 (2025): 28943–28954.

[142] M. M. Albariqi, S. Versteeg, E. M. Brakkee, et al., “Human IAPP Is a Contributor to Painful Diabetic Peripheral Neuropathy,” Journal of Clinical Investigation 133, no. 8 (2023): e156993.

[143] D. Milardi, E. Gazit, S. E. Radford, et al., “Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes,” Chem Rev 121, no. 3 (2021): 1845–1893.

[144] J. Kim, K. Park, M. J. Kim, et al., “An Autophagy Enhancer Ameliorates Diabetes of human IAPP-transgenic Mice Through Clearance of Amyloidogenic Oligomer,” Nature Communications 12, no. 1 (2021): 183.

[145] T. Wu, Y. Shao, X. Li, et al., “NR3C1/Glucocorticoid Receptor Activation Promotes Pancreatic Beta-cell Autophagy Overload in Response to Glucolipotoxicity,” Autophagy 19, no. 9 (2023): 2538–2557.

[146] B. Shashni, Y. Tajika, and Y. Nagasaki, “Design of Enzyme-responsive Short-chain Fatty Acid-based Self-assembling Drug for Alleviation of Type 2 Diabetes Mellitus,” Biomaterials 275 (2021): 120877.

[147] G. Milligan, N. Barki, and A. Tobin, “Chemogenetic Approaches to Explore the Functions of Free Fatty Acid Receptor 2,” Trends in Pharmacological Sciences 42, no. 3 (2021): 191–202.

[148] S. Li, Y. Duan, S. Luo, F. Zhou, Q. Wu, and Z. Lu, “Short-chain Fatty Acids and Cancer,” Trends in cancer 11, no. 2 (2025): 154–168.

[149] S. Yan, A. Santoro, M. J. Niphakis, et al., “Inflammation Causes Insulin Resistance in Mice via Interferon Regulatory Factor 3 (IRF3)-mediated Reduction in FAHFA Levels,” Nature Communications 15, no. 1 (2024): 4605.

[150] A. Nogal, F. Asnicar, A. Vijay, et al., “Genetic and Gut Microbiome Determinants of SCFA Circulating and Fecal Levels, Postprandial Responses and Links to Chronic and Acute Inflammation,” Gut Microbes 15, no. 1 (2023): 2240050.

[151] M. C. Blair, M. D. Neinast, C. Jang, et al., “Branched-chain Amino Acid Catabolism in Muscle Affects Systemic BCAA Levels but Not Insulin Resistance,” Nat Metab 5, no. 4 (2023): 589–606.

[152] P. M. Møller, R. Kjøbsted, M. H. Petersen, et al., “Effect of Acute Exercise and Exercise Training on the Ability of Insulin to Clear Branched-chain Amino Acids From Plasma in Obesity and Type 2 Diabetes,” Diabetologia 68, no. 8 (2025): 1789–1800.

[153] A. R. Verkerke, D. Wang, N. Yoshida, et al., “BCAA-nitrogen Flux in Brown Fat Controls Metabolic Health Independent of Thermogenesis,” Cell 187, no. 10 (2024): 2359–2374.

[154] D. Lee, E. Yoon, S. J. Ham, et al., “Diabetic Sensory Neuropathy and Insulin Resistance Are Induced by Loss of UCHL1 in Drosophila,” Nature Communications 15, no. 1 (2024): 468.

[155] X. Deng, C. Tang, T. Fang, et al., “Disruption of Branched-chain Amino Acid Homeostasis Promotes the Progression of DKD via Enhancing Inflammation and Fibrosis-associated Epithelial-mesenchymal Transition,” Metabolism 162 (2025): 156037.

[156] S. Lin, S. Wang, P. Wang, et al., “Bile Acids and Their Receptors in Regulation of Gut Health and Diseases,” Progress in Lipid Research 89 (2023): 101210.

[157] M. Cadena Sandoval and R. Haeusler, “Bile Acid Metabolism in Type 2 Diabetes Mellitus,” Nature reviews Endocrinology 21, no. 4 (2025): 203–213.

[158] Q. Wang, H. Lin, C. Shen, et al., “Gut Microbiota Regulates Postprandial GLP-1 Response via Ileal Bile Acid-TGR5 Signaling,” Gut Microbes 15, no. 2 (2023): 2274124.

[159] P. Li, R. Zhang, J. Zhou, P. Guo, Y. Liu, and S. Shi, “Vancomycin Relieves Tacrolimus-induced Hyperglycemia by Eliminating Gut Bacterial Beta-glucuronidase Enzyme Activity,” Gut Microbes 16, no. 1 (2024): 2310277.

[160] S. Wang, Q. Jia, X. Liu, et al., “Hyperoside Modulates Bile Acid and Fatty Acid Metabolism, Presenting a Potentially Promising Treatment for Non-alcoholic Fatty Liver Disease,” Journal of Advanced Research 80 (2026): 759–773.

[161] B. Han, X. Lv, G. Liu, et al., “Gut Microbiota-related Bile Acid Metabolism-FXR/TGR5 Axis Impacts the Response to Anti-alpha4beta7-integrin Therapy in Humanized Mice With Colitis,” Gut Microbes 15, no. 1 (2023): 2232143.

[162] S. Jacob, A. J. Krentz, J. Deanfield, and L. Rydén, “Evolution of Type 2 Diabetes Management From a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care,” Drugs 81, no. 12 (2021): 1373–1379.

[163] J. Ma, M. Li, L. Yang, et al., “Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy,” MedComm 6, no. 9: e70359 (2020).

[164] L. Barrea, L. Verde, A. Colao, L. J. Mandarino, and G. Muscogiuri, “Medical Nutrition Therapy for the Management of Type 2 Diabetes Mellitus,” Nature reviews Endocrinology 21, no. 12 (2025): 769–782.

[165] A. Elmaleh-Sachs, J. L. Schwartz, C. T. Bramante, J. M. Nicklas, K. A. Gudzune, and M. Jay, “Obesity Management in Adults: A Review,” Jama 330, no. 20 (2023): 2000–2015.

[166] D. Gallardo-Gómez, E. Salazar-Martínez, R. M. Alfonso-Rosa, et al., “Optimal Dose and Type of Physical Activity to Improve Glycemic Control in People Diagnosed with Type 2 Diabetes: A Systematic Review and Meta-analysis,” Diabetes Care 47, no. 2 (2024): 295–303.

[167] Q. Liu, Y. Hua, R. He, et al., “Restoration of Intestinal Secondary Bile Acid Synthesis: A Potential Approach to Improve Pancreatic Beta Cell Function in Type 1 Diabetes,” Cell Rep Med 6, no. 5 (2025): 102130.

[168] E. Steinbach, D. Masi, A. Ribeiro, P. Serradas, T. Le Roy, and K. Clément, “Upper Small Intestine Microbiome in Obesity and Related Metabolic Disorders: A New Field of Investigation,” Metabolism 150 (2024): 155712.

[169] D. P. Baars, M. F. Fondevila, A. S. Meijnikman, and M. Nieuwdorp, “The central Role of the Gut Microbiota in the Pathophysiology and Management of Type 2 Diabetes,” Cell Host & Microbe 32, no. 8 (2024): 1280–1300.

[170] B. A. Peters, Q. Qi, M. Usyk, et al., “Association of the Gut Microbiome With Kidney Function and Damage in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL),” Gut Microbes 15, no. 1 (2023): 2186685.

[171] L. Silamiķele, R. Saksis, I. Silamiķelis, et al., “Spatial Variation of the Gut Microbiome in Response to Long-term Metformin Treatment in High-fat Diet-induced Type 2 Diabetes Mouse Model of both Sexes,” Gut Microbes 15, no. 1 (2023): 2188663.

[172] S. B. Glaros, S. P. Mishra, S. Jain, et al., “Systemic and Gut Microbiome Changes With Metformin and Liraglutide in Youth-onset Type 2 Diabetes: The MIGHTY Study,” Gut Microbes 17, no. 1 (2025): 2558071.

[173] J. Muñoz-Pardeza, J. F. López-Gil, N. Huerta-Uribe, I. Hormazábal-Aguayo, M. Izquierdo, and A. García-Hermoso, “Nonpharmacological Interventions on Glycated Haemoglobin in Youth With Type 1 Diabetes: A Bayesian Network Meta-analysis,” Cardiovasc Diabetol 23, no. 1 (2024): 230.

[174] X. Zhao, M. Duaso, H. A. Ghazaleh, L. Cheng, and A. Forbes, “Effectiveness of Interventions for Improving Physical Activity Level in Working-age People (aged 18–60 years) With Type 2 Diabetes: A Systematic Review and Meta-analysis,” Lancet 402, no. Suppl 1 (2023): S97.

[175] L. Zhang, J. Zhang, and S. Yang, “Art Breaks Obesity's Health Information Silos,” Trends in Endocrinology and Metabolism 3612 (2025): 1059–1062.

[176] D. Bozkurt, M. Duaso, and J. Sturt, “Use of the 2021 UK Medical Research Council Guidance to Refine the Women's Wellness With Type 2 Diabetes Programme: A Mixed-methods Study,” Lancet 402, no. Suppl 1 (2023): S27.

[177] D. T. Sherifali, M. E. Racey, M. K. Greenway, et al., “Type 2 Diabetes Remission: A Systematic Review and Meta-analysis of Nonsurgical Randomized Controlled Trials,” Diabetes Care 48, no. 12 (2025): 2181–2191.

[178] N. Yoon and S. Diano, “Hypothalamic Glucose-sensing Mechanisms,” Diabetologia 64, no. 5 (2021): 985–993.

[179] M. Becker, S. Kälin, A. H. Neubig, et al., “Regulatory T Cells in the Mouse Hypothalamus Control Immune Activation and Ameliorate Metabolic Impairments in High-calorie Environments,” Nature Communications 16, no. 1 (2025): 2744.

[180] M. Sullivan, F. Fernandez-Aranda, L. Camacho-Barcia, et al., “Insulin and Disorders of Behavioural Flexibility,” Neuroscience and Biobehavioral Reviews 150 (2023): 105169.

[181] E. Brown, H. J. L. Heerspink, D. J. Cuthbertson, and J. P. H. Wilding, “SGLT2 inhibitors and GLP-1 Receptor Agonists: Established and Emerging Indications,” Lancet 398, no. 10296 (2021): 262–276.

[182] J. A. Ríos, J. C. Bórquez, J. A. Godoy, J. M. Zolezzi, M. C. Furrianca, and N. C. Inestrosa, “Emerging Role of Metformin in Alzheimer's Disease: A Translational View,” Ageing Research Reviews 100 (2024): 102439.

[183] E. Barroso, M. Montori-Grau, W. Wahli, X. Palomer, and M. Vázquez-Carrera, “Striking a Gut-liver Balance for the Antidiabetic Effects of metformin,” Trends in Pharmacological Sciences 44, no. 7 (2023): 457–473.

[184] M. Wang, H. Pan, Y. Huang, et al., “Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients with Type 2 Diabetes Treated with Metformin,” JAMA Network Open 5, no. 12 (2022): e2245854.

[185] T. Hsieh, H. Chen, W. Chang, and C. Ho, “Metformin-based Oral Antihyperglycemic Combination Therapy and Risk of Dementia in Patients With Newly Diagnosed Type 2 Diabetes: A Population-based Study,” Alzheimers Dement 21, no. 8 (2025): e70590.

[186] D. K. Burns, R. C. Alexander, K. A. Welsh-Bohmer, et al., “Safety and Efficacy of pioglitazone for the Delay of Cognitive Impairment in People at Risk of Alzheimer's Disease (TOMMORROW): A Prognostic Biomarker Study and a Phase 3, Randomised, Double-blind, Placebo-controlled Trial,” Lancet Neurology 20, no. 7 (2021): 537–547.

[187] H. Wang, R. L. Cordiner, Y. Huang, et al., “Cardiovascular Safety in Type 2 Diabetes with Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study,” Diabetes Care 46, no. 5 (2023): 967–977.

[188] M. Packer, C. S. P. Lam, J. Butler, F. Zannad, M. Vaduganathan, and B. A. Borlaug, “Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure with a Preserved Ejection Fraction?,” Journal of the American College of Cardiology 8620 (2025): 1917–1931.

[189] N. Marx, M. Husain, M. Lehrke, S. Verma, and N. Sattar, “GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes,” Circulation 146, no. 24 (2022): 1882–1894.

[190] F. Prattichizzo, P. de Candia, and A. Ceriello, “Diabetes and Kidney Disease: Emphasis on Treatment With SGLT-2 Inhibitors and GLP-1 Receptor Agonists,” Metabolism 120 (2021): 154799.

[191] Y. Xie, B. Bowe, H. Xian, T. Loux, J. B. McGill, and Z. Al-Aly, “Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Major Adverse Cardiovascular Events: Emulation of a Randomised Target Trial Using Electronic Health Records,” The Lancet Diabetes & Endocrinology 11, no. 9 (2023): 644–656.

[192] N. Marx, J. E. Deanfield, J. F. Mann, et al., “Oral Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial,” Circulation 151, no. 23 (2025): 1639–1650.

[193] J. B. Green, M. A. Bethel, P. W. Armstrong, et al., “Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes,” New England Journal of Medicine 373, no. 3 (2015): 232–242.

[194] H. Tang, S. E. Kimmel, S. M. Smith, et al., “Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results from Randomized Outcome Trials,” Diabetes Care 45, no. 4 (2022): 1007–1012.

[195] B. L. Neuen, R. A. Fletcher, L. Heath, et al., “Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis,” Circulation 150, no. 22 (2024): 1781–1790.

[196] S. H. Jeong, S. J. Chung, H. S. Yoo, et al., “Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Parkinson's Disease,” Brain 144, no. 4 (2021): 1127–1137.

[197] J. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso, “Acarbose for Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM Randomised Trial,” Lancet 359, no. 9323 (2002): 2072–2077.

[198] N. N. Nguyen, D. S. Ho, H. S. Nguyen, et al., “Preadmission Use of Antidiabetic Medications and Mortality Among Patients With COVID-19 Having Type 2 Diabetes: A Meta-analysis,” Metabolism 131 (2022): 155196.

[199] A. Albini, A. R. Cantelmo, L. Mortara, D. M. Noonan, and G. Corso, “Cancer Prevention and Interception With Antidiabetic and Anti-obesity Drugs: Current and Future Perspectives,” Seminars in Cancer Biology 115 (2025): 40–52.

[200] A. Philis-Tsimikas, R. M. Bergenstal, T. S. Bailey, et al., “Once-weekly Insulin Efsitora Alfa versus Once-daily Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3): A Phase 3, Randomised, Non-inferiority Trial,” Lancet 405, no. 10497 (2025): 2279–2289.

[201] D. Foer, P. E. Beeler, J. Cui, E. W. Karlson, D. W. Bates, and K. N. Cahill, “Asthma Exacerbations in Patients With Type 2 Diabetes and Asthma on Glucagon-Like Peptide-1 Receptor Agonists,” American Journal of Respiratory and Critical Care Medicine 203, no. 7 (2021): 831–840.

[202] A. Qaseem, A. J. Obley, T. Shamliyan, et al., “Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians,” Annals of Internal Medicine 177, no. 5 (2024): 658–666.

[203] E. D'Andrea, D. J. Wexler, S. C. Kim, J. M. Paik, E. Alt, and E. Patorno, “Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients with Type 2 Diabetes and Varying Baseline HbA1c Levels,” JAMA Internal Medicine 183, no. 3 (2023): 242–254.

[204] J. M. Dennis, K. G. Young, A. P. McGovern, et al., “Development of a Treatment Selection Algorithm for SGLT2 and DPP-4 Inhibitor Therapies in People With Type 2 Diabetes: A Retrospective Cohort Study,” Lancet Digit Health 4, no. 12 (2022): e873–e883.

[205] G. K. Dawwas, J. H. Flory, S. Hennessy, C. E. Leonard, and J. D. Lewis, “Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis,” Diabetes Care 45, no. 4 (2022): 919–927.

[206] A. van der Aart-van der Beek, R. de Boer, and H. Heerspink, “Kidney and Heart Failure Outcomes Associated With SGLT2 Inhibitor Use,” Nature Reviews Nephrology 18, no. 5 (2022): 294–306.

[207] P. Rossing, S. E. Inzucchi, P. Vart, et al., “Dapagliflozin and New-onset Type 2 Diabetes in Patients With Chronic Kidney Disease or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials,” The Lancet Diabetes & Endocrinology 10, no. 1 (2022): 24–34.

[208] F. Lezoualc'h, L. Badimon, H. Baker, et al., “Diabetic Cardiomyopathy: The Need for Adjusting Experimental Models to Meet Clinical Reality,” Cardiovascular Research 119, no. 5 (2023): 1130–1145.

[209] C. Eyileten, Z. Wicik, D. Keshwani, et al., “Alteration of Circulating Platelet-related and Diabetes-related microRNAs in Individuals With Type 2 Diabetes Mellitus: A Stepwise Hypoglycaemic Clamp Study,” Cardiovasc Diabetol 21, no. 1 (2022): 79.

[210] A. P. Courcoulas, M. E. Patti, B. Hu, et al., “Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes,” Jama 331, no. 8 (2024): 654–664.

[211] M. Nayor, S. H. Shah, V. Murthy, and R. V. Shah, “Molecular Aspects of Lifestyle and Environmental Effects in Patients with Diabetes: JACC Focus Seminar,” Journal of the American College of Cardiology 78, no. 5 (2021): 481–495.

[212] J. Rosenstock, C. Wysham, J. P. Frías, et al., “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-blind, Randomised, Phase 3 Trial,” Lancet 398, no. 10295 (2021): 143–155.

[213] Reduced Insulin Use and Diabetes Complications Upon Introduction of SGLT-2 Inhibitors and GLP1-receptor Agonists in Low- and Middle-income Countries: A Microsimulation, Plos Medicine 2025. 22(4): e1004559.

[214] V. R. Aroda, H. Krause-Steinrauf, E. J. Kazemi, et al., “Clinical and Metabolic Characterization of Adults with Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort,” Diabetes Care 45, no. 7 (2022): 1512–1521.

[215] R. J. Chakkalakal, K. I. Galaviz, S. Thirunavukkarasu, M. K. Shah, and K. V. Narayan, “Test and Treat for Prediabetes: A Review of the Health Effects of Prediabetes and the Role of Screening and Prevention,” Annual Review of Public Health 45, no. 1 (2024): 151–167.

[216] M. Nauck, J. Wefers, and J. Meier, “Treatment of Type 2 Diabetes: Challenges, Hopes, and Anticipated Successes,” The Lancet Diabetes & Endocrinology 9, no. 8 (2021): 525–544.

[217] R. Sekar, K. Motzler, Y. Kwon, et al., “Vps37a regulates Hepatic Glucose Production by Controlling Glucagon Receptor Localization to Endosomes,” Cell metabolism 34, no. 11 (2022): 1824–1842.e9.

[218] B. Yau, J. Ghislain, M. A. Kebede, J. Hughes, and V. Poitout, “The Role of the Beta Cell in Type 2 Diabetes: New Findings From the Last 5 Years,” Diabetologia 68, no. 10 (2025): 2092–2103.

[219] L. K. Billings, F. Andreozzi, M. Frederiksen, et al., “Once-weekly IcoSema versus Multiple Daily Insulin Injections in Type 2 Diabetes Management (COMBINE 3): An Open-label, Multicentre, Treat-to-target, Non-inferiority, Randomised, Phase 3a Trial,” The Lancet Diabetes & Endocrinology 13, no. 7 (2025): 556–567.

[220] D. Gupta, A. W. Burstein, D. C. Schwalbe, et al., “Ghrelin Deletion and Conditional Ghrelin Cell Ablation Increase Pancreatic Islet Size in Mice,” Journal of Clinical Investigation 133, no. 24 (2023): e169349.

[221] R. Eckel, K. Bornfeldt, and I. Goldberg, “Cardiovascular Disease in Diabetes, Beyond Glucose,” Cell metabolism 33, no. 8 (2021): 1519–1545.

[222] Impact of Diabetes on the Effects of Sodium Glucose co-transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-analysis of Large Placebo-controlled Trials, Lancet 2022. 400(10365): 1788–1801.

[223] G. Filippatos, S. D. Anker, R. Agarwal, et al., “Finerenone Reduces Risk of Incident Heart Failure in Patients with Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial,” Circulation 145, no. 6 (2022): 437–447.

[224] S. Taylor, Z. Yazdi, and A. Beitelshees, “Pharmacological Treatment of Hyperglycemia in Type 2 Diabetes,” Journal of Clinical Investigation 131, no. 2 (2021): e142243.

[225] E. K. Oikonomou, E. S. Spatz, M. A. Suchard, and R. Khera, “Individualising Intensive Systolic Blood Pressure Reduction in Hypertension Using Computational Trial Phenomaps and Machine Learning: A Post-hoc Analysis of Randomised Clinical Trials,” Lancet Digit Health 4, no. 11 (2022): e796–e805.

[226] M. D. Kelsey, A. J. Nelson, J. B. Green, et al., “Guidelines for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes: JACC Guideline Comparison,” Journal of the American College of Cardiology 79, no. 18 (2022): 1849–1857.

[227] D. Prakoso, M. J. De Blasio, M. Tate, and R. H. Ritchie, “Current Landscape of Preclinical Models of Diabetic Cardiomyopathy,” Trends in Pharmacological Sciences 43, no. 11 (2022): 940–956.

[228] A. J. Nelson, E. C. O'Brien, L. A. Kaltenbach, et al., “Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease,” JAMA Network Open 5, no. 2 (2022): e2148030.

[229] N. J. Pagidipati, A. J. Nelson, L. A. Kaltenbach, et al., “Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial,” Jama 329, no. 15 (2023): 1261–1270.

[230] B. Neuen, M. Oshima, R. Agarwal, et al., “Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized,” Controlled Trials Circulation 145, no. 19 (2022): 1460–1470.

[231] A. Ashfaq, M. Meineck, A. Pautz, E. Arioglu-Inan, J. Weinmann-Menke, and M. C. Michel, “A Systematic Review on Renal Effects of SGLT2 Inhibitors in Rodent Models of Diabetic Nephropathy,” Pharmacology & Therapeutics 249 (2023): 108503.

[232] J. A. Udell, W. S. Jones, M. C. Petrie, et al., “Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week,” Journal of the American College of Cardiology 79, no. 20 (2022): 2058–2068.

[233] P. Narongkiatikhun and P. Bjornstad, “Deciphering the Kidney Hemodynamic Effects of SGLT2 Inhibition: Translating Insights From Rats to Humans in Type 2 Diabetes,” Kidney International 106, no. 3 (2024): 354–356.

[234] Y. Wada, K. Kidokoro, M. Kondo, et al., “Evaluation of Glomerular Hemodynamic Changes by Sodium-glucose-transporter 2 Inhibition in Type 2 Diabetic Rats Using in Vivo Imaging,” Kidney International 106, no. 3 (2024): 408–418.

[235] K. Tuttle, “Digging Deep Into Cells to Find Mechanisms of Kidney Protection by SGLT2 Inhibitors,” Journal of Clinical Investigation 133, no. 5 (2023): e167700.

[236] D. van Raalte, P. Bjornstad, D. Z. I. Cherney, et al., “Combination Therapy for Kidney Disease in People With Diabetes Mellitus,” Nature Reviews Nephrology 20, no. 7 (2024): 433–446.

[237] G. Liu, Y. Li, A. Pan, et al., “Adherence to a Healthy Lifestyle in Association with Microvascular Complications among Adults with Type 2 Diabetes,” JAMA Network Open 6, no. 1 (2023): e2252239.

[238] D. Wang, J. Li, G. Luo, et al., “Nox4 as a Novel Therapeutic Target for Diabetic Vascular Complications,” Redox Biology 64 (2023): 102781.

[239] J. Maghfour, J. Mineroff, D. M. Ozog, et al., “Evidence-based Consensus on the Clinical Application of Photobiomodulation,” Journal of the American Academy of Dermatology 93, no. 2 (2025): 429–443.

[240] L. J. Oost, A. A. van der Heijden, E. A. Vermeulen, et al., “Serum Magnesium Is Inversely Associated with Heart Failure, Atrial Fibrillation, and Microvascular Complications in Type 2 Diabetes,” Diabetes Care 44, no. 8 (2021): 1757–1765.

[241] L. Zhao, H. Hu, L. Zhang, et al., “Inflammation in Diabetes Complications: Molecular Mechanisms and Therapeutic Interventions,” MedComm 2024, no. 4 (2020): e516.

[242] Y. Zhou, W. Jia, J. Bi, et al., “Sulfated Hyaluronic Acid/Collagen-based Biomimetic Hybrid Nanofiber Skin for Diabetic Wound Healing: Development and Preliminary Evaluation,” Carbohydrate Polymers 334 (2024): 122025.

[243] B. Jeong, W. Choi, W. Choi, et al., “A Male Mouse Model for Metabolic Dysfunction-associated Steatotic Liver Disease and Hepatocellular Carcinoma,” Nature Communications 15, no. 1 (2024): 6506.

[244] G. Targher, A. Mantovani, C. D. Byrne, and H. Tilg, “Recent Advances in Incretin-based Therapy for MASLD: From Single to Dual or Triple Incretin Receptor Agonists,” Gut 74, no. 3 (2025): 487–497.

[245] J. Wu, W. Hsu, C. Kuo, et al., “A Retrospective Analysis of Combination Therapy With GLP-1 Receptor Agonists and SGLT2 Inhibitors versus SGLT2 Inhibitor Monotherapy in Patients With MASLD,” Nature Communications 16, no. 1 (2025): 7459.

[246] H. Xia, Y. Min, Y. Wang, et al., “Multiparametric MRI Evaluation of Liver Fat and Iron After Glucagon-Like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model,” Radiology 316, no. 2 (2025): e243780.

[247] Y. Shi, S. U. Kim, T. C. Yip, et al., “Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals with T2D and MASLD,” Clinical Gastroenterology and Hepatology 243 (2026): 723–732.e10.

[248] C. Celsa, G. Pennisi, A. Tulone, et al., “Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With a Lower Risk of Major Adverse Liver-related Outcomes: A Meta-analysis of Observational Cohort Studies,” Gut 74, no. 5 (2025): 815–824.

[249] S. V. Badve, A. Bilal, M. M. Y. Lee, et al., “Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta-analysis of Randomised Controlled Trials,” The Lancet Diabetes & Endocrinology 13, no. 1 (2025): 15–28.

[250] Y. C. Kudva, D. Raghinaru, J. W. Lum, et al., “A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes,” New England Journal of Medicine 392, no. 18 (2025): 1801–1812.

[251] A. I. Adler, R. L. Coleman, J. Leal, W. N. Whiteley, P. Clarke, and R. R. Holman, “Post-trial Monitoring of a Randomised Controlled Trial of Intensive Glycaemic Control in Type 2 Diabetes Extended From 10 Years to 24 Years (UKPDS 91),” Lancet 404, no. 10448 (2024): 145–155.

[252] M. S. Usman, D. L. Bhatt, I. Hameed, et al., “Effect of SGLT2 Inhibitors on Heart Failure Outcomes and Cardiovascular Death Across the Cardiometabolic Disease Spectrum: A Systematic Review and Meta-analysis,” The Lancet Diabetes & Endocrinology 12, no. 7 (2024): 447–461.

[253] K. W. M. Abeysekera, L. Valenti, Z. Younossi, et al., “Implementation of a Liver Health Check in People With Type 2 Diabetes,” Lancet Gastroenterol Hepatol 9, no. 1 (2024): 83–91.

[254] M. Munshi, A. R. Kahkoska, J. J. Neumiller, et al., “Realigning Diabetes Regimens in Older Adults: A 4S Pathway to Guide Simplification and Deprescribing Strategies,” The Lancet Diabetes & Endocrinology 13, no. 5 (2025): 427–437.

[255] S. Xie, S. Liu, T. Zhang, et al., “USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart,” Circulation 149, no. 9 (2024): 684–706.

[256] N. Staplin, A. J. Roddick, B. L. Neuen, et al., “Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis,” JAMA (2025): e2520835.

[257] B. M. Shields, J. M. Dennis, C. D. Angwin, et al., “Patient Stratification for Determining Optimal Second-line and Third-line Therapy for Type 2 Diabetes: The TriMaster Study,” Nature Medicine 29, no. 2 (2023): 376–383.

[258] H. L. A. Janssen, Y. Lim, P. Lampertico, et al., “Switching to tenofovir Alafenamide in Patients With Virologically Suppressed Chronic hepatitis B and Renal or Hepatic Impairment: Final Week 96 Results From an Open-label, Multicentre, Phase 2 Study,” Lancet Gastroenterol Hepatol 9, no. 8 (2024): 718–733.

[259] D. Q. Huang, N. Noureddin, V. Ajmera, et al., “Type 2 Diabetes, Hepatic Decompensation, and Hepatocellular Carcinoma in Patients With Non-alcoholic Fatty Liver Disease: An Individual Participant-level Data Meta-analysis,” Lancet Gastroenterol Hepatol 8, no. 9 (2023): 829–836.

[260] J. L. Januzzi, R. Mohebi, Y. Liu, et al., “Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial,” Circulation 148, no. 8 (2023): 651–660.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.